Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter cardiac safety study of liposomal mitoxantrone hydrochloride in advanced malignant tumors
CTR20212546Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in Nonhematologic neoplasms, peripheral T-cell lymphoma (PTCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Oct 2021; status: active.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
Nonhematologic neoplasmsperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20212546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212546.